Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS-2: tirzepatide versus semaglutide added to metformin in type 2 diabetes
MOH_2019-08-15_007244Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tirzepatide, semaglutide and metformin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Started Jun 2019; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2019-08-15_007244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-08-15_007244.